ACE I/D polymorphism in Czech first-wave SARS-CoV-2-positive survivors

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F21%3A00081143" target="_blank" >RIV/00023001:_____/21:00081143 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/68407700:21460/21:00357387 RIV/00216224:14110/21:00121855

Výsledek na webu

<a href="https://reader.elsevier.com/reader/sd/pii/S0009898121001492?token=283ED33899916EABDFDE0226449A3E7CAC3DC2C945AF5D35DBF3E4DC9AD9035C6F9C8007DBCC21FCA3778B3F721F2EE2&originRegion=eu-west-1&originCreation=20210728102456" target="_blank" >https://reader.elsevier.com/reader/sd/pii/S0009898121001492?token=283ED33899916EABDFDE0226449A3E7CAC3DC2C945AF5D35DBF3E4DC9AD9035C6F9C8007DBCC21FCA3778B3F721F2EE2&originRegion=eu-west-1&originCreation=20210728102456</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.cca.2021.04.024" target="_blank" >10.1016/j.cca.2021.04.024</a>

Jazyk výsledku

angličtina

Název v původním jazyce

ACE I/D polymorphism in Czech first-wave SARS-CoV-2-positive survivors

Popis výsledku v původním jazyce

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rapidly spread from China in 2019/ 2020 to all continents. Significant geographical and ethnic differences were described, and host genetic background seems to be important for the resistance to and mortality of COVID-19. Angiotensin-converting enzyme (ACE) insertion/deletion (I/D) polymorphism (rs4646994) is one of the candidates with the potential to affect infection symptoms and mortality. Methods: In our study, we successfully genotyped 408 SARS-CoV-2-positive COVID-19 survivors (163 asymptomatic and 245 symptomatic) and compared them with a population-based DNA bank of 2,559 subjects. Results: The frequency of ACE I/I homozygotes was significantly increased in COVID-19 patients compared with that in controls (26.2% vs. 21.2%; P = 0.02; OR [95% CI] = 1.55 [1.17-2.05]. Importantly, however, the difference was driven just by the symptomatic subjects (29.0% vs. 21.2% of the I/I homozygotes; P = 0.002; OR [95% CI] = 1.78 [1.22-2.60]). The genotype distribution of the ACE genotypes was almost identical in population controls and asymptomatic SARS-CoV-2-positive patients (P = 0.76). Conclusions: We conclude that ACE I/D polymorphism could have the potential to predict the severity of COVID19, with I/I homozygotes being at increased risk of symptomatic COVID-19.

Název v anglickém jazyce

ACE I/D polymorphism in Czech first-wave SARS-CoV-2-positive survivors

Popis výsledku anglicky

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rapidly spread from China in 2019/ 2020 to all continents. Significant geographical and ethnic differences were described, and host genetic background seems to be important for the resistance to and mortality of COVID-19. Angiotensin-converting enzyme (ACE) insertion/deletion (I/D) polymorphism (rs4646994) is one of the candidates with the potential to affect infection symptoms and mortality. Methods: In our study, we successfully genotyped 408 SARS-CoV-2-positive COVID-19 survivors (163 asymptomatic and 245 symptomatic) and compared them with a population-based DNA bank of 2,559 subjects. Results: The frequency of ACE I/I homozygotes was significantly increased in COVID-19 patients compared with that in controls (26.2% vs. 21.2%; P = 0.02; OR [95% CI] = 1.55 [1.17-2.05]. Importantly, however, the difference was driven just by the symptomatic subjects (29.0% vs. 21.2% of the I/I homozygotes; P = 0.002; OR [95% CI] = 1.78 [1.22-2.60]). The genotype distribution of the ACE genotypes was almost identical in population controls and asymptomatic SARS-CoV-2-positive patients (P = 0.76). Conclusions: We conclude that ACE I/D polymorphism could have the potential to predict the severity of COVID19, with I/I homozygotes being at increased risk of symptomatic COVID-19.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30303 - Infectious Diseases

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2021

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Clinica chimica acta

ISSN

0009-8981

e-ISSN

—

Svazek periodika

519

Číslo periodika v rámci svazku

August

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

4

Strana od-do

206-209

Kód UT WoS článku

000659205000008

EID výsledku v databázi Scopus

2-s2.0-85106338177